ASLAN Pharmaceuticals Price to Book Ratio 2017-2021 | ASLN

Historical price to book ratio values for ASLAN Pharmaceuticals (ASLN) over the last 10 years. The current price to book ratio for ASLAN Pharmaceuticals as of October 22, 2021 is 0.74.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

ASLAN Pharmaceuticals Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 1.47 1.26
2021-03-31 3.35 $1.17 2.87
2020-12-31 1.83 $-0.24 -7.56
2020-09-30 1.90 $-0.30 -6.25
2020-06-30 2.00 $-0.21 -9.50
2020-03-31 1.02 0.00
2019-12-31 2.03 $-0.02 -127.67
2019-09-30 1.73 0.00
2019-06-30 3.07 0.00
2019-03-31 4.29 $0.82 5.22
2018-12-31 3.60 $0.96 3.77
2018-09-30 7.98 $1.29 6.17
2018-06-30 8.90 $1.69 5.27
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.056B $0.003B
ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76